Ciclesonide的全球市場: 規模，佔有率，展望，機會分析(2022年～2028年)

全球Ciclesonide的市場規模，由於過敏性鼻炎和氣喘的高盛行率，主要地區的頻繁產品認證，主要企業的策略性M&A增加等所促進。

本報告提供全球Ciclesonide市場調查，市場概要，市場規模和預測，趨勢，成長要素，阻礙因素，各適應症、劑型、地區的分析，及競爭情形等資訊。

目錄

第1章 調查目的、前提條件

• 調查目的
• 假設
• 簡稱

第2章 市場概要

• 報告的說明
  • 市場定義和範圍
• 摘要整理
  • 市場明細:各適應症
  • 市場明細:各劑型
  • 市場明細:各地區
• Coherent Opportunity Map(COM)

第3章 市場動態，法規，及趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 市場趨勢
• 新產品的認證與發售

第4章 全球Ciclesonide市場:各適應症(2017年～2028年)

• 簡介
• 過敏性鼻炎
• 氣喘

第5章 全球Ciclesonide市場:各劑型(2017年～2028年)

• 簡介
• 氣霧劑
• 滴鼻劑

第6章 全球Ciclesonide市場:各地區(2017年～2028年)

• 簡介
• 北美
• 美國
• 加拿大
• 歐洲
• 英國
• 德國
• 義大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 日本
• 印度
• ASEAN
• 澳洲
• 韓國
• 其他亞太地區
• 南美
• 巴西
• 墨西哥
• 阿根廷
• 其他南美國家
• 非洲
• 北非
• 中非
• 南非
• 中東
• GCC各國
• 以色列
• 其他中東

第7章 競爭情形

• 熱圖分析
• 企業簡介
  • AstraZeneca Plc
• 未來的策略
  • Cipla Limited
• 未來的策略
  • Sun Pharmaceutical Industries Ltd.
• 未來的策略
  • Apotex Inc.
• 未來的策略

第8章 Section

Ciclesonide is an inhaled corticosteroids (ICS), recommended in asthma and chronic obstructive pulmonary disease (COPD) indication to get relief from difficulty in breathing, chest tightness, wheezing, and coughing. Inhaled drugs including inhaled corticosteroids, long acting B2 adrenoceptor agonists (LABA), and long acting muscarinic receptor antagonists (LAMA) are important treatment regime in the management of COPD. Inhaled corticosteroids are generally considered as safe and well tolerated in both adults and children. The improved safety and comparable efficacy profiles of ciclesonide demonstrated a potential treatment option which may lead to improved adherence and treatment outcome in asthma and COPD.

However, some of the studies raised concerns regarding increased risk of pneumonia related to regular use of ICS in adult patients with chronic obstructive pulmonary disease. A study findings published in the Respirology Journal: 2013, revealed an increased risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma regularly taking ICS. This could potentially lead to restrict application of ciclesonide by patients during the forecast period.

Market Dynamics

Factors such as high prevalence of allergy rhinitis and asthma, and frequent product approval and launches in key regions are expected to drive the market growth over the forecast period. For instance, according to the Global Asthma Report published in 2021, it was estimated that globally asthma kills around 1,000 people every day and affects as many as 339 million people, worldwide. Furthermore, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol indicated for treatment of allergic rhinitis and launched it in the U.S. market.

Moreover, increasing strategic mergers and acquisitions by key players is also expected to support and drive the market growth. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).

Key features of the study:

• This report provides in-depth analysis of ciclesonide market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global ciclesonide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study includes AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics.
• The global ciclesonide market report caters to various stakeholders in this industry including investors, researchers, ciclesonide manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the ciclesonide market.

Detailed Segmentation:

• Global Ciclesonide Market, By Indication:
• Allergy Rhinitis
• Asthma
• Global Ciclesonide Market, By Dosage Form:
• Aerosol
• Nasal Spray
• Global Ciclesonide Market, By Geography:
• North America
  • By Country:
• U.S.
• Canada
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Europe
  • By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Asia Pacific
  • By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Latin America
  • By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Middle East
  • By Country:
• GCC
• Israel
• Rest of Middle East
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Africa
  • By Country:
• North Africa
• Central Africa
• South Africa
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Company Profiles
• AstraZeneca Plc*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments
  • Strategies
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Indication
  • Market Snippet, By Dosage Form
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• New Product Approvals & Launches

4. Global Ciclesonide Market, By Indication, 2017-2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Allergy Rhinitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
• Asthma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)

5. Global Ciclesonide Market, By Dosage Form, 2017-2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Aerosol
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
• Nasal Spray
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)

6. Global Ciclesonide Market, By Region, 2017-2028, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, By Region, 2017 - 2028
• North America
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• U.S.
• Canada
• Europe
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• China
• Japan
• India
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Africa
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• North Africa
• Central Africa
• South Africa
• Middle East
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• GCC Countries
• Israel
• Rest of Middle East

7. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • AstraZeneca Plc
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies
  • Cipla Limited
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies
  • Apotex Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies

8. Section

• References
• Research Methodology
• About Us and Sales Contact